NDNatalia Dardzińska

Natalia Dardzińska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Natalia Dardzińska has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Incretin-Based Therapies and the Associated Impact on Bone Health

    by Krzysztof Łupina, Miłosz Bronowski, Natalia Dardzińska, Paulina Jaskulska, Adrian Nowak, Anna Romac, Piotr Różański, Jakub Janczura

    Incretin-based therapies are being increasingly used in the treatment of type 2 diabetes mellitus and obesity, both of which are associated with impaired bone quality, altered skeletal remodeling, and increased fracture risk. Experimental studies suggest that incretin signaling may affect bone through osteoblast and osteoclast activity, Wnt/β-catenin signaling, adipose tissue inflammation, metabolic regulation, and the gut–bone axis. However, clinical evidence remains heterogeneous, with most studies indicating neutral or context-dependent effects on bone mineral density and fracture risk rather than consistent skeletal benefit. Interpretation is further complicated by treatment-induced weight loss, changes in lean mass and mechanical loading, diabetes-related skeletal fragility, and the limited number of trials specifically designed to assess bone endpoints. Evidence for newer dual and triple agonists is especially limited, despite their growing use and substantial weight-loss effects. Incretin-based therapies appear reassuring from a skeletal safety perspective; however, long-term studies with dedicated skeletal endpoints are needed to determine their effects on bone quality, falls, and fracture risk in high-risk populations. This review summarizes current mechanistic, preclinical, and clinical evidence on the effects of glucagon-like peptide-1 receptor agonists, dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors on bone turnover, bone mineral density, bone quality, and fracture outcomes.

  • Open Access

    Unusual presentation of small bowel obstruction in Cowden syndrome: A case report and literature review

    by Natalia Dardzińska, Emil ObręBski, Dominika Lorek, Paulina Jaskulska, Natalia Krzysztofek, Kamil Jończyk, Bartosz Molasy

    Intestinal intussusception in adults is a rare disorder, occurring in about 5% of cases. In the pediatric population, it is most often idiopathic in origin, while in adults it is associated with pathologies within the intestinal wall. The purpose of this study is to emphasize the need for expanded diagnosis in adult patients with symptoms of gastrointestinal obstruction due to intestinal intussusception. The medical records of a 22-year-old female patient hospitalized in the Department of General Surgery of St. Alexander Hospital in Kielce were analyzed. The patient presented to the hospital with complaints of abdominal pain accompanied by vomiting. She had a history of treatment for Hashimoto’s disease, iron deficiency anemia and gastritis. After initial diagnosis, the patient was transferred to the department of general surgery, where conservative treatment was implemented and gastroscopy was performed. During hospitalization, the patient was consulted in internal medicine due to uncompensated hypothyroidism. Due to lack of improvement, imaging studies were ordered, which revealed a dilated loop of small intestine with suspected intussusception. The patient was qualified for surgery, during which an intussusception of the jejunum was found. Due to the inability to drain the intussusception, a segmental small bowel resection was performed. Histopathological examination revealed a hamartomatous polyp as the cause of the intussusception. Given the overall clinical picture, the patient was referred to the genetic counseling center, where Cowden syndrome was confirmed. Intestinal intussusception, although rare, should be considered as a cause of gastrointestinal obstruction in adults. Identification of the pathological changes that are its cause is crucial to the overall diagnostic and therapeutic process.

  • Open Access

    Implementation of noninvasive liver disease screening tools in primary care

    by Klaudia Nowak, Adrian Nowak, Aleksandra Jabłońska, Anna Potaczek, Julia Salacha, Natalia Dardzińska, Jakub Janczura

    The global increase in the incidence of metabolic dysfunction-associated steatotic liver disease (MASLD), which affects more than one-third of the general population and up to 70% of individuals with type 2 diabetes or obesity, is a critical public health challenge. Given that liver steatosis is often asymptomatic until the advanced stages of disease, early detection is essential to prevent its progression to fibrosis, cirrhosis and, ultimately, hepatocellular carcinoma. However, liver biopsy, the gold-standard diagnostic method, is invasive, costly, and unsuitable for large-scale screening. As a result, noninvasive tests have emerged as practical alternatives, particularly in primary care settings, where early identification is most feasible. The present study explored current perspectives of noninvasive liver disease screening tools and their implementation in primary care. Serum-based indices, along with imaging techniques, have demonstrated promise in identifying patients with advanced fibrosis. Novel biomarkers, including the enhanced liver fibrosis test and Pro-C3, as well as emerging artificial intelligence-assisted diagnostic platforms, yield improved accuracy and risk stratification potential. Despite accumulating evidence supporting the clinical utility and cost-effectiveness of noninvasive tests, several barriers hinder their routine use in primary care settings, which include limited funding, lack of standardized guidelines, insufficient clinician training, and disparities in access to diagnostic tools. The implementation of structured stepwise screening models has demonstrated improved diagnostic efficiency and reduced unnecessary referrals. Future research should emphasize the integration of artificial intelligence, portable diagnostic devices, and personalized risk models to enhance early detection. Ensuring widespread adoption requires coordinated efforts in policy development, provider education, and health-system investment. Noninvasive screening tools offer a feasible and cost-effective pathway for the early detection of MASLD in primary care; however, their successful implementation depends on addressing logistical, educational, and systemic barriers.


  • Open Access

    Various GLP-1 Receptor Agonist Preference Use with a Special Focus on Oral and Subcutaneous Forms in Poland

    by Klaudia Nowak, Artur Dziewierz, Aleksandra Sojda, Michał Zabojszcz, Łukasz Szarpak, Natalia Dardzinska, Paulina Jaskulska, Zbigniew Siudak

    Background: Since the introduction of the first GLP-1 receptor agonist (GLP-1 RA) in 2005, there has been a steady increase in the number of drugs available in this group, as well as an expansion of their indications and routes of administration. Aim: The aim of the study was to assess the clinical characteristics of patients treated with GLP-1 RA in Poland in 2018–2024, with particular emphasis on the disease entities constituting indications for treatment (like obesity and diabetes), and to analyse the frequency of use of individual drugs during the study period. Methods: A cohort study was conducted based on anonymised medical data from 300 outpatient clinics the largest private healthcare facilities in Poland (Luxmed), on consecutive patients who had at least one prescription for GLP-1 RA. The analysis covered the period from 1 January 2018 to 31 December 2024. Results: The number of patients using GLP-1 RA increased from 212 in 2018 to 12,836 in 2024. Obesity was diagnosed in 78% of all patients, most often in the groups using liraglutide and tirzepatide. The highest percentage of patients with type 2 diabetes was observed in the dulaglutide group (67%), while the lowest was in the tirzepatide group (15%). From 2022, the share of oral semaglutide steadily increased, reaching 50% of all semaglutide applications in 2024 in Poland. Conclusions: In the analysed group, GLP-1 RAs were most commonly used to treat obesity. The oral form of semaglutide was more frequently used in younger females with less aggravating medical history.